Inhaled liposomal amphotericin-B as a prophylactic treatment for COVID-19-associated pulmonary aspergillosis/aspergillus tracheobronchitis

Crit Care. 2021 Aug 19;25(1):298. doi: 10.1186/s13054-021-03728-w.

Sofie Van Ackerbroeck¹, Lynn Rutsaert^{1

2}, Ella Roelant^{3

4}, Kathleen Dillen⁵, Joost Wauters⁶, Niels Van Regenmortel^{7

8}

¹ Department of Intensive Care Medicine, Ziekenhuis Netwerk Antwerpen Campus Stuivenberg, Lange Beeldekensstraat 267, 2060, Antwerp, Belgium.
² Department of Haematology, Gasthuiszusters Antwerpen, Campus St. Augustinus, Oosterveldlaan 24, 2610, Wilrijk, Belgium.
³ Center for Statistics, StatUa, University of Antwerp, Prinsstraat 13, 2000, Antwerp, Belgium.
⁴ Clinical Trial Center (CTC), CRC Antwerp, Antwerp University Hospital, University of Antwerp, Drie Eikenstraat 655, 2650, Edegem, Belgium.
⁵ Department of Pharmacy, Ziekenhuis Netwerk Antwerpen Campus Stuivenberg, Lange Beeldekensstraat 267, 2060, Antwerp, Belgium.
⁶ Medical Intensive Care Unit, Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium.
⁷ Department of Intensive Care Medicine, Ziekenhuis Netwerk Antwerpen Campus Stuivenberg, Lange Beeldekensstraat 267, 2060, Antwerp, Belgium. niels.vanregenmortel@zna.be.
⁸ Department of Intensive Care Medicine, Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Antwerp, Belgium. niels.vanregenmortel@zna.be.

No abstract available

Publication types